4th How to Diagnose and Treat
Acute Leukaemias
March 1-3, 2024 – Stockholm, Sweden
Chairs: Hervé Dombret, Gert Ossenkoppele, Christoph Röllig, Wendy Stock

Friday, March 1, 2024

08:00-08:05	**Welcome**	Conference chairpersons
08:05-08:45	**Keynote lecture** **Chair:** Hervé Dombret (Paris)	
08:05-08:35	How do the new WHO / ICC /ELN classifications impact clinical decision making?	Richard Stone (Boston)
08:35-08:45	*Discussion*	

SESSION I – Diagnosis and treatment of rare diseases
Chair: Wendy Stock (Chicago)

08:45-09:00	Interactive case: Germ-line-mutation-based AML	Marie Sebert (Paris)
09:00-09:05	*Discussion*	
09:05-09:25	Case-based lecture: Blastic plasmacytoid dendritic cell neoplasm	Andrew Lane (Boston)
09:25-09:30	*Discussion*	
09:30-09:50	Case-based lecture: Extramedullary / CNS relapse in ALL	Nicolas Boissel (Paris)
09:50-09:55	*Discussion*	
09:55-10:15	Case-based lecture: Mixed phenotypic acute leukemias: for example: MPAL with t(v;11q23.3); KMT2A-rearranged	Etan Orgel (Los Angeles)
10:15-10:20	*Discussion*	
10:20-10:25	Brief oral communication *Successful remission induction in a primary refractory pediatric MLLT10::PICALM acute leukemia by targeted BCL-2 inhibition identified by para-clinical pharmacotyping*	Alexandra Niedermayer (Ulm)
10:25-10:28	*Discussion*	
10:28-10:50	*Panel discussion*	
10:50-11:20	***Coffee break and Poster viewing***	

SESSION II – Novel treatments
Chair: Agnieszka Wierzbowska (Lodz)

11:20-11:35	Interactive case: Frontline Blinatumumab for all in ALL?	Mark Litzow (Rochester)
11:35-11:40	*Discussion*	
11:40-12:00	Case-based lecture: Menin inhibitors	Eunice Wang (Buffalo)
12:00-12:05	*Discussion*	
12:05-12:25	Case-based lecture: MRD directed therapy- a new therapeutic option	Andrew Wei (Melbourne)
12:25-12:30	*Discussion*	
12:30-12:50	Case-based lecture: BH3 mimetics in ALL	Kristen O'Dwyer (Rochester)
12:50-12:55	*Discussion*	
12:55-13:00	Brief oral communication *Phase 1 Dose-Escalation Study of GFH009 in Acute Myeloid Leukemia*	*Tapan Kadia (Houston)*
13:00-13:03	*Discussion*	
13:03-13:25	*Panel discussion*	
13:25-15:20	***Lunch***	

14:10-15:10 **SATELLITE SYMPOSIUM**
Interactive case studies for an IDH1 mutated patient ineligible for intensive chemotherapy – From diagnosis to treatment
Chair: Courtney DiNardo (Houston)
Speakers: Courtney DiNardo (Houston), Lars Fransecky (Kiel), Adriano Venditti (Rome)

This symposium is organised and sponsored by Servier

SESSION III – Dilemmas in AML
Chair: Christoph Röllig (Dresden)

15:20-15:35	Interactive case: Relapse after VenAza	Lionel Adès (Paris)
15:35-15:40	*Discussion*	
15:40-16:00	Case-based Lecture: What to do with TP53-mut AML?	David Sallman (Tampa)
16:00-16:05	*Discussion*	
16:05-16:25	Case-based lecture: Management of FL3+AML after allo HCT	Alexander Perl (Philadelphia)
16:25-16:30	*Discussion*	
16:30-16:50	Case-based lecture: Post remission treatment in MRD-negative intermediate risk AML	Adriano Venditti (Rome)
16:50-16:55	*Discussion*	
16:55-17:00	Brief oral communication *Real-world outcomes of refractory AML*	*Markus Liew-Littorin (Örebro)*
17:00-17:03	*Discussion*	

17:03-17:25 *Panel discussion*

17:25-17:55 ***Coffee break and Poster viewing***

17:55-18:35 **DEBATE 1 – MRD conversion before allo SCT**
Chair: Jordi Esteve (Barcelona)

Audience votes

17:55-18:10	PRO	Chris Hourigan (Bethesda)
18:10-18:25	CON	Charles Craddock (Birmingham)
18:25-18:35	*Discussion*	

Audience votes again

18:35-19:15 **ROUNDTABLE 1 – Innovative trial designs to accelerate advances in leukaemia**
Chair: Andrew Wei (Melbourne)

18:35-18:50	Bayesian approach	Lucie Biard (Paris)
18:50-19:05	Real world derived control arm vs experimental arm	Megan Othus (Seattle)
19:05-19:15	*Discussion*	

19:15-20:30 ***Poster Walks and Welcome Get Together stand-up buffet dinner***
Poster leaders:
- *Jordi Esteve (Barcelona), Kristen O'Dwyer (Rochester)*
- *Caner Saygin (Chicago), Marie Sebert (Paris)*

Saturday, March 2, 2024

09:00-10:00 **3 Simultaneous Breakfast Meet the Expert Sessions**

1.	Maintenance treatment in AML	Andrew Wei (Melbourne)
2.	Optimal Use of Asparaginase in adults with ALL?	Nicola Gökbuget (Frankfurt)
3.	Molecular diagnostics: What is needed at diagnosis and for monitoring?	Richard Stone (Boston)

10:00-10:30 ***Coffee Break and Poster viewing***

SESSION IV – Immunotherapy in AML and ALL
Chair: Wendy Stock (Chicago)

10:30-10:45	Interactive case: The challenge to immune targeting of AML	Marion Subklewe (Munich)
10:45-10:50	*Discussion*	
10:50-11:10	Case-based lecture: Is antibody targeting sufficient therapy for older adults with B-ALL?	Matthew J. Wieduwilt (Oklahoma City)

11:10-11:15 *Discussion*

11:15-11:35 Case-based lecture: Nicola Gökbuget (Frankfurt)
Inotuzumab versus Blinatumomab as 1L options in ALL
11:35-11:40 *Discussion*

11:40-12:00 Case-based lecture: Lori Muffly (Stanford)
Novel antibody and CAR-T-Cell approaches in ALL
12:00-12:05 *Discussion*

12:05-12:10 Brief oral communication *Iveta Oravcova (Bratislava)*
Clinical analysis of allogeneic stem cell transplantations in adult patients with acute myeloid leukemia - 10 years of institutional experience.

12:10-12:13 Discussion

12:13-12:35 Panel discussion

12:35-14:05 Lunch

14:05-14:45 ROUNDTABLE 2 – VenAza or intensive chemo as 1L treatment before allo HCT
Chair: Christoph Röllig (Dresden)

14:05-14:20 VenAza as first line treatment before allo Keith Pratz (Philadelphia)

14:20-14:35 Intensive chemo Agnieszka Wierzbowska (Lodz)

14:35-14:45 *Discussion*

14:45-16:00 DEBATE 2 – Transplant is no longer first line approach to Ph+ ALL
Chair: Hervé Dombret (Paris)

Audience votes

14:45-15:00 PRO Sabina Chiaretti (Rome)

15:00-15:15 CON Yves Chalandon (Geneva)

15:15-15:25 *Discussion*

Audience votes again

15:25-15:55 Coffee break and Poster viewing

SESSION V – Clonal haematopoiesis and germline predisposition
Chair: Gert Ossenkoppele (Amsterdam)

15:55-16:10 Interactive case: Dave de Leeuw (Amsterdam)
The relevance of the value of CHIP mutation in remission
16:10-16:15 *Discussion*

16:15-16:35 Case-based lecture: Gerwin Huls (Groningen)
Clonal cytopenia of unknown significance (CCUS)
16:35-16:40 *Discussion*

16:40-17:00	Case-based lecture: Controversies around donor selection and CHIP	Michael Drazer (Chicago)
17:00-17:05	*Discussion*	
17:05-17:25	Case-based lecture: Red flags for germline predisposition	Marc Raaijmakers (Rotterdam)
17:25-17:30	*Discussion*	
17:30-17:35	Brief oral communication *A rare case of familial CEBPA-mutant acute myeloid leukemia*	*Frini Karaolidou (Athens)*
17:35-17-38	*Discussion*	
17:38-18:00	*Panel discussion*	

Sunday, March 3, 2024

08:55-09:55 3 Simultaneous Breakfast Meet the Expert Sessions

1. ALL management in elderly patients — Matthew J. Wieduwilt (Winston-Salem)
2. MRD in AML: State of the art — Adriano Venditti (Rome)
3. Frontline use of Gemtuzumab Ozogamicin — Hervé Dombret (Paris)

09:55-10:25 Coffee break and Poster viewing

SESSION VI- Leukaemia treatment challenges
Chair: Eunice Wang (Buffalo)

10:25-10:40	Interactive case: First R/R AML in fit AML	Judith Schaffrath (Halle)
10:40-10:45	*Discussion*	
10:45-11:05	Case-based lecture: Therapy related ALL	Caner Saygin (Chicago)
11:05-11:10	*Discussion*	
11:10-11:30	Case-based lecture: Relapse post allo HCT	Jordi Esteve (Barcelona)
11:30-11:35	*Discussion*	
11:35-11:55	Case-based lecture: Steroid-refractory GVHD	Daniel Wolff (Regensburg)
11:55-12:00	*Discussion*	
12:00- 12:05	*Brief oral communication* *The role of venetoclax combinations in acute myeloid leukemia - treatment patterns and real-world outcomes*	*Marta Pires Lima (Lisbon)*
12:05-12:08	*Discussion*	
12:08-12:30	*Panel discussion*	

12:30-12:40 Closing remarks

MEETING CLOSURE